《異動股》愛康醫療(01789.HK)春立醫療(01858.HK)急漲近24%-26% 成交急增
內地關節集採方案出爐。主要研發及產售植入性骨科醫療器械的春立醫療(01858.HK)價量齊呈異動,股價一舉突破10天、20天及牛熊線(26.9-30.9元),最高見31.7元,創七個月高,現造31.4元,急升25.6%,成交急增至285萬股已創逾兩個月高,涉資8,415萬元。
主要從事設計、開發及產售骨科植入物及相關產品的愛康醫療(01789.HK)一舉升破四條主要多動平均線(50天線爲13.1元),最高見14.9元,現造14.84元,急漲近24%,成交急增至1,983萬股,涉資2.8億元。
國家組織高值醫用耗材聯合採購辦公室發佈《國家組織人工關節集中帶量採購公告(第1號)》,由天津市醫藥採購中心實施人工關節集中帶量採購。採購品種爲採購產品爲初次置換人工全髖關節、初次置換人工全膝關節,週期爲2年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.